Explore our comprehensive portfolio that addresses the complete care continuum for many of the world’s most threatening diseases. 

Discover the stories of pioneers pushing the boundaries of what’s possible in healthcare to help improve people’s lives around the world.

Patient-centered innovation has been and always will be at the core of our company. Dive deeper into our fascinating technologies.

We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably. Learn more about our purpose, our innovation leadership, our culture, and our strategy.

  1. Home

  2. Press center
  3. Press releases
  4. Siemens Healthineers closes fiscal year with strong fourth quarter
Press release

Siemens Healthineers closes fiscal year with strong fourth quarter

Siemens Healthineers AG today announces its results for the fourth quarter of fiscal year 2023 ended September 30, 2023, and the full fiscal year 2023.
Published on November 8, 2023

Fiscal Year 2023 – Targets achieved for revenue growth and earnings per share 

  • Excellent equipment book-to-bill ratio of 1.15 
  • Outstanding comparable revenue growth of 8.3% excluding rapid COVID-19 antigen tests; including the rapid antigen-test business, which ended in the fourth quarter, comparable revenue increase of 1.2% 
  • Remarkable comparable revenue growth at Varian of 14.8%; clear growth in the Imaging segment of 10.9% and Advanced Therapies of 7.8%; due to the discontinued business with rapid COVID-19 antigen tests, Diagnostics recorded a decrease of 24.2% 
  • Adjusted EBIT margin excluding rapid COVID-19 antigen tests of 14.0% roughly on a par with the prior-year level; adjusted EBIT margin including rapid antigen tests of 14.2%; adjusted EBIT decreased to €3.1 billion, mainly due to the lower contribution from rapid antigen tests 
  • Adjusted basic earnings per share €2.02 
  • Proposed dividend of €0.95 per share, unchanged from previous year

Q4 Fiscal Year 2023 – Double-digit revenue growth and higher earnings at Varian and Imaging 

  • Excellent equipment book-to-bill ratio of 1.16 
  • Outstanding comparable revenue growth of 10.8% excluding rapid COVID-19 antigen tests; including the discontinued business with rapid antigen tests, comparable revenue increase of 7.5% 
  • Imaging achieved comparable revenue growth of 10.6%; adjusted EBIT margin of 22.4% 
  • Diagnostics reported comparable revenue growth of 1.6% excluding rapid COVID-19 antigen tests; including the rapid antigen-test business, which ended in the fourth quarter, comparable revenue decline of 10.6%; adjusted EBIT margin of 2.0% 
  • Varian had sharp comparable revenue growth of 29.8%; adjusted EBIT margin of 18.7% 
  • Advanced Therapies showed comparable revenue growth of 5.1%; adjusted EBIT margin of 17.5% 
  • Overall adjusted EBIT margin excluding rapid COVID-19 antigen tests of 16.3%, approximately 160 basis points above prior-year quarter; overall adjusted EBIT margin including rapid antigen tests of 16.7% 
  • Adjusted basic earnings per share €0.58 

Outlook1) for Fiscal Year 2024 

For fiscal year 2024, we expect comparable revenue growth of between 4.5% to 6.5% compared with fiscal year 2023. Excluding revenue from rapid COVID-19 antigen tests, this corresponds to comparable revenue growth of between 5.0% and 7.0%. We expect adjusted basic earnings per share to be between €2.10 and €2.30 

Bernd Montag, CEO of Siemens Healthineers AG: 

»We have delivered a very strong final quarter of another successful year at Siemens Healthineers. I am very proud of the team and the trust we have earned with our customers.«

Download Quarterly Statement(pdf, 292.63 KB)
1

Starting in fiscal year 2024, the definitions of adjusted EBIT margin and adjusted basic earnings per share will be adapted. For more information, please refer to the Q4 2023 analyst conference presentation. The assumptions on which the outlook is based can be found on page 8 in this document.

Siemens Healthineers 2023

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies are continuously developing their product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care. In fiscal 2022, which ended on September 30, 2022, Siemens Healthineers, which has approximately 69,500 employees worldwide, generated revenue of around €21.7 billion and adjusted EBIT of almost €3.7 billion. Further information is available at www.siemens-healthineers.com.